Endoscopic abnormalities in the oesophagus after variceal sclerotherapy--a long-term follow up study.
Endoscopic sclerotherapy is a well-established treatment modality for oesophageal varices. Various local, regional and systemic complications occur after sclerotherapy. Altered endoscopic appearances of the oesophagus have been observed on follow-up of patients after sclerotherapy. 171 consecutive patients with extra-hepatic portal venous obstruction on follow up after achieving variceal eradication by sclerotherapy during the period from January 2004 to June 2005 were enrolled in this study. The oesophagus was closely observed for mucosal abnormalities and the endoscopic findings were recorded. Out of 171 patients, 95 (55.5%) patients had no specific endoscopic changes in the oesophagus. The most common finding was mucosal neovascularization which was seen in 56 (32.7%) patients. Oval or oblong depressed areas were seen in 41 (23.9%) patients. Mucosal tags and polypoidal lesions were seen in 37 (21.6%) patients. 25 (15.6%) patients had stenosis of the lower oesophagus and 3 (1.7%) patients had mucosal bridges. On multivariate analysis, these abnormal endoscopic findings in the oesophagus correlated with the total volume of sclerosant injected when compared with those patients without similar findings on endoscopy (p value < 0.001). Endoscopic sclerotherapy leads to various abnormalities at the injection sites like neovascularization, oval or oblong depressed areas, mucosal tags, polypoidal lesions, stenosis and mucosal bridges. Endoscopic abnormalities correlated with the total volume of sclerosant used. The long-term significance of these changes is not known at present and further follow-up studies will be required.
Thomas
Varghese
V
Department of Gastroenterology, Medical College Hospital, Calicut - 673 008, Kerala, India. drvarghesethomas@gmail.com
Tony
Jose
J
Harish
K
K
Harikumar
R
R
Sunilkumar
K
K
D000328:Adult; D016099:Endoscopy, Gastrointestinal; D004932:Esophageal and Gastric Varices / Q000473:pathology / Q000628:therapy*; D004947:Esophagus / Q000187:drug effects / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy / Q000379:methods*; D012720:Severity of Illness Index; D012981:Sodium Tetradecyl Sulfate / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D012597:Sclerosing Solutions; D012981:Sodium Tetradecyl Sulfate